CB Fleet voluntarily recalls OTC OSP
This article was originally published in The Tan Sheet
Executive Summary
CB Fleet, maker of the lone OTC oral sodium phosphate product, voluntarily recalls its Fleet Phospho-soda products following FDA's safety alert on the kidney injury risks associated with using the products for bowel cleansing. The recall "is directed to retailers and wholesalers" and Fleet decided "voluntarily to remove them from the market as expeditiously as possible," the Lynchburg, Va.-based firm says Dec. 11, referencing FDA's alert (1"The Tan Sheet" Dec. 15, 2008, p. 8). Fleet requests that consumers not purchase the OTC products for bowel cleansing and says to contact physicians for alternatives if an OTC is doctor-recommended
You may also be interested in...
OTC Monograph Reform Could ‘Unlock’ Innovations In Three Years
Following enactment of US OTC monograph reform, drug companies will unleash formulation innovations after keeping a lid on monograph R&D, CHPA anticipates. "A lot of companies have ideas like this they’ve kind of put in a drawer, that we think this is gonna unlock,” says David Spangler, an executive with the OTC trade group.
OTC Monograph Reform Could ‘Unlock’ Innovations In Three Years
Following enactment of US OTC monograph reform, drug companies will unleash formulation innovations after keeping a lid on monograph R&D, CHPA anticipates. "A lot of companies have ideas like this they’ve kind of put in a drawer, that we think this is gonna unlock,” says David Spangler, an executive with the OTC trade group.
OTC Monograph Reform Could ‘Unlock’ Innovations In Three Years
Following enactment of US OTC monograph reform, drug companies will unleash formulation innovations after keeping a lid on monograph R&D, CHPA anticipates. "A lot of companies have ideas like this they’ve kind of put in a drawer, that we think this is gonna unlock,” says David Spangler, an executive with the OTC trade group.